13th edition

Format
HYBRID

December 3rd & 4th, 2024

IN-PERSON | LILLE, FR

December 11th& 12th 2024

ONLINE MEETINGS

2024 Speakers

We are seeking for speakers to share their experience, expertise, opinions and best practices in BioFIT conferences.
If you are interested, please contact us.

Learn more about BioFIT 2024 speakers

Over 60 international experts from academia, industry and biotech addressed issues to learn about the latest trends and explore hands-on approaches to tech transfer and open innovation in the field of Life Sciences, by sharing their experience and knowledge and keeping these goals in mind: Entail new partnerships, source innovative and competitive early-stage R&D projects, facilitate the emergence of collaborative projects and increase licensing opportunities in the field of Life Sciences.

Eric Wyart

Eric Wyart

Operational Director
BelgiumRéseau LiEU

Eric Wyart is the Operational Director of the LiEU Network, the network of technology and knowledge transfer offices of the French-speaking universities in Belgium (TTO/KTO). After completing his engineering degree from the Université Libre de Bruxelles, he began his career at Cenaero when the centre had just been created in 2002. He completed his doctoral thesis on the industrialization of crack propagation computation methods for aeronautical structures under the supervision of Professors Pardoen and Remacle at the Université catholique de Louvain.

Subsequently, he was successively in charge of the Metallic Structures & Processes and Computational Multiphysics Software Development teams at Cenaero. During this period, he contributed to the setting up of regional and European projects while pursuing actions to promote and raise awareness among companies. Activities he led until his departure for the R&D center of Plastic Omnium where he was in charge of the multiphysics design platform dedicated to fuel tanks.

Eric Wyart

Operational Director
BelgiumRéseau LiEU
Farzad Abdi-Dezfuli

Farzad Abdi-Dezfuli

Partner
NorwaySarsia

As one of the founders of Sarsia, and the principal analyst regarding life science investments, Farzad brings nearly 30 years of drug development expertise and management from large global pharma and early-stage start-ups. Farzad’s experience spans multiple national and global preclinical and clinical drug development initiatives at both administrative and Board levels. In addition to receiving training in entrepreneurial business financing from London Business School, Farzad obtained his doctoral education in pharmacology from the University of Edinburgh Medical School, UK and postdoctoral training from HaukelandUniversity Hospital Bergen, Norway.

Farzad Abdi-Dezfuli

Partner
NorwaySarsia
Jürgen Walkenhorst

Jürgen Walkenhorst

Manager Patents and Licenses
GermanyPROvendis GmbH

Jürgen studied biology/molecular biology in Osnabrück and Aberdeen (UK). After his diploma thesis at the EMBL in Heidelberg, he worked at Genentech, Inc. (USA). He undertook his PhD-thesis at the Max-Planck-Institute for Developmental Biology in Tübingen. He joined Cellzome AG (Heidelberg, now part of GSK) as the first employee where he was instrumental in setting up the company and was later responsible for IP-issues. After a stint in the patent department of Baxter AG in Vienna, he changed to technology transfer. At Austria Wirtschaftsservice GmbH, Vienna, he was managing life science inventions developed at Austrian universities.

In 2007, he moved to PROvendis, the central technology transfer agency of the universities of the German state of North Rhine-Westphalia, where during most of his time he served as a head of the Life sciences team. In between, he stayed for another one and a half years in Vienna, as head of technology transfer at the University of Vienna and furthermore for about one and a half years as Managing Director of Life Science Nord, the cluster organisation of the life science industry in the German states of Hamburg and Schleswig-Holstein.

He also holds a Master´s degree in Pharmaceutical Business Development and Licensing from the University of Manchester.

Jürgen Walkenhorst

Manager Patents and Licenses
GermanyPROvendis GmbH
Markus Lang

Markus Lang

Managing Director
GermanyDr Lang Consulting

Dr Lang Consulting GmbH brings 20 years of experience in pharmaceutical R&D, the successful development, manufacture and registration of biopharmaceutical drugs (focus on oncology and immunology).

Founder and Managing Director Dr. Markus A. Lang has profound leadership experience and successful P&L management of development portfolios in medium-sized companies as well as corporate environments in the biotech & pharmaceutical industry.

He made key contributions to successful development of several marketed drugs [Monjuvi®, Cyltezo®, Removab®, Pradaxa®]

As biotech entrepreneur Dr. Markus A. Lang supports companies in the areas of

  • Venture Development
  • C-Level Biotech Management. Organizational development
  • Preparation & execution of fundraising campaigns
  • Development and execution of drug development strategies
  • Lifecycle Focus: Late Discovery through (early) Preclinical to Phase I IND Readiness and/or phase II PoCC
  • Therapeutic entities: Biologics, ADCs and other moieties in primarily oncological and immunological disorders

Markus Lang

Managing Director
GermanyDr Lang Consulting
Paul Bravetti

Paul Bravetti

CEO
FranceBrenus Pharma

Paul Bravetti (PharmD, HEC Paris) is a strategic executive with a particular interest in scientific innovation and entrepreneurial adventures.

With his international experience in major pharmaceutical companies, which has shaped his understanding of the biopharmaceutical industry, he has successfully led the launches of therapeutics in immuno-oncology and biomolecular diagnostics across Europe and Asia. He joined Brenus Pharma in 2020 and became Chief Executive Officer in 2022 with a clear vision, mission, and leadership to address current unmet needs and make a significant impact for cancer patients.”

Brenus Pharma is a French clinical-stage biotech developing a pioneering technology platform, Stimulated-Tumor-Cell (STC).

STC is designed to generate ‘off-the-shelf’ and ‘first-in-class’ therapeutic cancer vaccine leading the way to a new precision medicine in immuno-oncology.

Brenus Pharma is on the brink of a breakthrough and will start its first-in-human study in 2024 in colorectal cancer, 2nd cause of cancer-related deaths worldwide.

We are building a strong portfolio in solid tumors, leveraging our patented STC platform, to change a paradigm in oncology.

Paul Bravetti

CEO
FranceBrenus Pharma

Contact

Eline Delcroix

Scroll to Top
  • No products in the cart.